Skip to main content
Contact CVRx Contact CVRx

Clinical results

ESC EJHF manuscript thumbnail

BeAT-HF publication

View / Download

Hospitalization data

View / Download

QOL data

View / Download

LVEF data

View / Download

BeAT-HF trial

Sustained symptomatic improvements

Barostim plus GDMT provides significant and meaningful improvements for heart failure patients beyond GDMT alone

+44 Meters at
12 months

Nominal p-value < 0.001

Exercise capacity
(6MHW)1

exercise capacity(6mhw) chart from the beat-hf trial
-10 Points at 24 months

Nominal p-value < 0.001

Quality of life
(MLWHF)1

quality of life (mlwhf) chart from the beat-hf trial
27% More patients improved at 24 months

Nominal p-value < 0.001

Functional status
(NYHA class)1

functional status (nyha class) chart from the beat-hf trial

Freedom from all-cause death,
LVAD, and transplant1

34% Relative Reduction

HR 0.662 (95% CI 0.435, 1.007)
nominal p=0.054

Patients in the Barostim arm had a 34% reduction in all-cause death or the use of LVAD or heart transplant at > 4 years follow-up

freedom from all-cause death, LVAD, and transplant chart from the beat-hf trial

Safe procedure1

97%

Freedom from major adverse neurological or cardiovascular system or procedure-related event rate in the Barostim arm

1. Zile MR, et al. Eur J Heart Fail. 2024 Apr 12; 2. Gremeaux V, et al. Arch Phys Med Rehabil. 2011;92(4):611-619.; 3. Rector TS, et al. J Card Fail. 1995;1(3):201-216;